Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.
Dieter Zopf
Advertisement
Articles by Dieter Zopf
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the rationale for a study of regorafenib (Stivarga) combinations in pediatric patients with rhabdomyosarcomas (RMS).
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the optimal partner for regorafenib (Stivarga) in pediatric rhabdomyosarcomas.
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.
Advertisement
Latest Updated Articles
Identification of Combinations For Pediatric RhabdomyosarcomasPublished: October 22nd 2018 | Updated:
Optimal Regorafenib Combinations in Pediatric RhabdomyosarcomasPublished: November 2nd 2018 | Updated:
Rationale for Regorafenib Combination Study in Pediatric RhabdomyosarcomaPublished: November 9th 2018 | Updated:
Clinical Development of Regorafenib Combinations in Pediatric RhabdomyosarcomaPublished: November 27th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5